Regeneron, Bayer to co-develop Eylea combination treatment

[riky]

Regeneron, Bayer to co-develop Eylea combination treatment

(Reuters) - U.S. based-Regeneron Pharmaceuticals Inc and Germany's Bayer AG said they would co-develop an antibody for use in combination with Eylea, their treatment for a form of age-related blindness. Bayer's unit, Bayer HealthCare, will pay Regeneron $25.5 million upfront and share global development costs for the program, the companies said in a joint statement. Both the Eylea injection and the new combination treatment is to treat wet age-related macular degeneration (wet AMD) - the leading cause of blindness in the elderly. "Given the multi-factorial nature of wet AMD, there is a potential for additional benefits to patients by addressing different pathways responsible for this devastating condition", Bayer HealthCare global development head Kemal Malik said.

Source: You are not allowed to view links. Register or Login